Zobrazeno 1 - 10
of 107
pro vyhledávání: '"Masaaki Fukuda"'
Autor:
Kanako Sakaeda, Koji Kurose, Yuki Matsumura, Satoshi Muto, Minoru Fukuda, Nanae Sugasaki, Masaaki Fukuda, Shinnosuke Takemoto, Hirokazu Taniguchi, Takeshi Masuda, Katsuhiko Shimizu, Yuki Kataoka, Yasuhiro Irino, Yumiko Sakai, Yusuke Atarashi, Masatoshi Yanagida, Noboru Hattori, Hiroshi Mukae, Masao Nakata, Eiichiro Kanda, Toru Oga, Hiroyuki Suzuki, Mikio Oka
Publikováno v:
Cancer Treatment and Research Communications, Vol 40, Iss , Pp 100830- (2024)
Background: NY-ESO-1 and XAGE1 cancer/testis antigens elicit humoral and cellular immune responses in NSCLC patients. We aimed to predict clinical benefit with ICI monotherapy, using an automated immunoassay of NY-ESO-1/XAGE1 antibodies (Abs). Method
Externí odkaz:
https://doaj.org/article/fa49acdde51b426e87156baacb0661b1
Autor:
Takaya Ikeda, Shinnosuke Takemoto, Hiroaki Senju, Hiroshi Gyotoku, Hirokazu Taniguchi, Midori Shimada, Yosuke Dotsu, Yasuhiro Umeyama, Hiromi Tomono, Takeshi Kitazaki, Masaaki Fukuda, Hiroshi Soda, Hiroyuki Yamaguchi, Minoru Fukuda, Hiroshi Mukae
Publikováno v:
Thoracic Cancer, Vol 11, Iss 7, Pp 1972-1978 (2020)
Background The aim of this study was to assess the efficacy and safety of amrubicin for previously treated malignant pleural mesothelioma. Methods The eligibility criteria were: previously treated unresectable malignant pleural mesothelioma; performa
Externí odkaz:
https://doaj.org/article/b8beb7e2f14e48d293606d434ed3eea7
Autor:
Shinnosuke Takemoto, Minoru Fukuda, Hiroyuki Yamaguchi, Takaya Ikeda, Kazumasa Akagi, Hiromi Tomono, Yasuhiro Umeyama, Yosuke Dotsu, Hirokazu Taniguchi, Hiroshi Gyotoku, Hiroaki Senju, Takeshi Kitazaki, Katsumi Nakatomi, Seiji Nagashima, Masaaki Fukuda, Akitoshi Kinoshita, Hiroshi Soda, Hiroshi Mukae
Publikováno v:
Thoracic Cancer, Vol 11, Iss 2, Pp 389-393 (2020)
Introduction Anti‐vascular endothelial growth factor therapy has been shown to be effective in non‐small cell lung cancer (NSCLC) patients with malignant pleural effusion (MPE); however, there are no data to suggest that ramucirumab has the same
Externí odkaz:
https://doaj.org/article/d24e897c795f4ec7ae6caea7a72c8675
Autor:
Hirokazu Taniguchi, Hiroyuki Yamaguchi, Yosuke Dotsu, Midori Shimada, Hiroshi Gyotoku, Hiroaki Senju, Shinnosuke Takemoto, Takeshi Kitazaki, Masaaki Fukuda, Daiki Ogawara, Hiroshi Soda, Katsumi Nakatomi, Nanae Sugasaki, Akitoshi Kinoshita, Seiji Nagashima, Takaya Ikeda, Yoichi Nakamura, Noriho Sakamoto, Yasushi Obase, Minoru Fukuda, Hiroshi Mukae
Publikováno v:
Thoracic Cancer, Vol 10, Iss 9, Pp 1764-1769 (2019)
Background The first‐line treatment for squamous cell lung cancer (SCC) has not necessarily been established; however, our previous exploratory study suggested that the combination of nedaplatin and amrubicin would be a promising treatment approach
Externí odkaz:
https://doaj.org/article/a4c5fc3cc43545d99dee8994a4d745d0
Publikováno v:
Journal of Advanced Mechanical Design, Systems, and Manufacturing, Vol 2, Iss 4, Pp 504-512 (2008)
A textural surface pattern is used to add a physical or decorative function to an object's surface. We have proposed a milling technique involving patch division that can quickly generate a geometric surface pattern using a common profile-forming met
Externí odkaz:
https://doaj.org/article/980ca1eea2fe476b9002f066855a9b74
Autor:
Hiroshi Soda, Hirokazu Taniguchi, Shinnosuke Takemoto, Hiroyuki Yamaguchi, Masaaki Fukuda, Hiroshi Gyotoku, Yosuke Dotsu, Minoru Fukuda, Hiromi Tomono, Hiroshi Mukae, Hiroaki Senju, Takeshi Kitazaki, Yasuhiro Umeyama, Takaya Ikeda, Midori Shimada
Publikováno v:
Thoracic Cancer, Vol 11, Iss 7, Pp 1972-1978 (2020)
Thoracic Cancer
Thoracic Cancer
Background The aim of this study was to assess the efficacy and safety of amrubicin for previously treated malignant pleural mesothelioma. Methods The eligibility criteria were: previously treated unresectable malignant pleural mesothelioma; performa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66845e4c665cad36f433116e1a955d87
https://doaj.org/article/b8beb7e2f14e48d293606d434ed3eea7
https://doaj.org/article/b8beb7e2f14e48d293606d434ed3eea7
Autor:
Hiroshi Gyotoku, Shinnosuke Takemoto, Yasuhiro Umeyama, Takaya Ikeda, Hiroyuki Yamaguchi, Minoru Fukuda, Hiroshi Mukae, Hirokazu Taniguchi, Akitoshi Kinoshita, Hiromi Tomono, Kazumasa Akagi, Hiroaki Senju, Takeshi Kitazaki, Hiroshi Soda, Seiji Nagashima, Masaaki Fukuda, Yosuke Dotsu, Katsumi Nakatomi
Publikováno v:
Thoracic Cancer, Vol 11, Iss 2, Pp 389-393 (2020)
Thoracic Cancer
Thoracic Cancer
Introduction Anti-vascular endothelial growth factor therapy has been shown to be effective in non-small cell lung cancer (NSCLC) patients with malignant pleural effusion (MPE); however, there are no data to suggest that ramucirumab has the same effe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae7e7db555f297967c16ca7727599e78
https://doaj.org/article/d24e897c795f4ec7ae6caea7a72c8675
https://doaj.org/article/d24e897c795f4ec7ae6caea7a72c8675
Autor:
Mikio Oka, Noboru Hattori, Midori Isobe, Ryohei Nozawa, Takeshi Masuda, Masao Nakata, Takahiro Karasaki, Hirokazu Matsushita, Kazuhiro Kakimi, Masaaki Fukuda, Katsuhiko Shimizu, Junichiro Futami, Akitoshi Kinoshita, Minoru Fukuda, Isao Irei, Koji Kurose, Yoshihiro Ohue, Hiroyuki Yamaguchi, Takaaki Yamaoka
Publikováno v:
Journal of Thoracic Oncology. 14:2071-2083
Introduction: Programmed cell death-1 (PD-1) inhibitors effectively treat NSCLC and prolong survival. Robust biomarkers for predicting clinical benefits of good response and long survival with anti–PD-1 therapy have yet to be identified; therefore,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2a19b8d451c14b311713b2d3cf79c0a
https://doi.org/10.1016/j.jtho.2019.08.008
https://doi.org/10.1016/j.jtho.2019.08.008
Autor:
Kanako Sakaeda, Koji Kurose, Minoru Fukuda, Nanae Sugasaki, Akitoshi Kinoshita, Takashi Kitazaki, Masaaki Fukuda, Takeshi Masuda, Noboru Hattori, Yusuke Atarashi, Yumiko Sakai, Yasuhiro Irino, Mami Yamaki, Toshiyuki Sato, Hiroshi Mukae, Toru Oga, Mikio Oka
Publikováno v:
Cancer Immunology Research. 10:A61-A61
Introduction: Immunotherapy with immune checkpoint inhibitors (ICI) is the standard of care for advanced non-small-cell lung cancer (NSCLC) without driver gene alterations. However, survival benefits with ICI are limited to a small subset of NSCLC pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4b2129e583d169953b5c6e154575382
https://doi.org/10.1158/2326-6074.tumimm22-a61
https://doi.org/10.1158/2326-6074.tumimm22-a61
Autor:
Takaya Ikeda, Katsumi Nakatomi, Akitoshi Kinoshita, Nanae Sugasaki, Hiroshi Gyotoku, Yosuke Dotsu, Noriho Sakamoto, Seiji Nagashima, Daiki Ogawara, Midori Shimada, Yasushi Obase, Hiroaki Senju, Hirokazu Taniguchi, Yoichi Nakamura, Masaaki Fukuda, Takeshi Kitazaki, Minoru Fukuda, Hiroshi Mukae, Shinnosuke Takemoto, Hiroyuki Yamaguchi, Hiroshi Soda
Publikováno v:
Thoracic Cancer, Vol 10, Iss 9, Pp 1764-1769 (2019)
Thoracic Cancer
Thoracic Cancer
BACKGROUND The first-line treatment for squamous cell lung cancer (SCC) has not necessarily been established; however, our previous exploratory study suggested that the combination of nedaplatin and amrubicin would be a promising treatment approach f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c4e986d0e623623883c12d387e33ea3
https://doaj.org/article/a4c5fc3cc43545d99dee8994a4d745d0
https://doaj.org/article/a4c5fc3cc43545d99dee8994a4d745d0